Merck Patent Gmbh

Ratiopharm Gmbh

Biogenerix Ag

Bioggnerix Ag

Stefan Arnold

Walter Mier

Armin Kuebelbeck

Gregor Larbig

Uwe Haberkorn

Walter Hinderer

Okke Franssen

Dietmar Eichinger

Christian Scheckermann

Nanni Jelinek

Albert Mekking

The present invention relates to a conjugate containing at least one kidney-selective carrier molecule and at least one active compound which has a protective action for the kidney against nephrotoxic active compounds, to a process for the preparation of the conjugate, to the use thereof for the protection of the kidney against nephrotoxic active compounds, and to a medicament comprising the conjugate.

Conjugates for protection from nephrotoxic active substances

The present invention relates to a peptide which consists of more than 50% of sequence sections of the formula -(A-B-C)-, and to a conjugate containing the peptide and at least one covalently bonded active compound, and to a process for the preparation of the conjugate. The present invention furthermore relates to the use of the peptide and the conjugate for targeting of the kidney, and to a medicament comprising the peptide or conjugate.

Peptides and peptide/active compound conjugates for renal targeting

The present invention relates to a method for purifying a recombinant follicle stimulating hormone (FSH) or recombinant FSH variant. The method comprises the steps of subjecting a liquid containing a recombinant FSH or recombinant FSH variant to an anion exchange chromatography, to a hydrophobic interaction chromatography, and to a dye affinity chromatography, wherein these chromatographies may be performed in any order, and wherein the method neither comprises a weak anion exchange chromatography nor a reverse phase chromatography. The method of purification results in a high yield of recombinant FSH having a desired degree of purity. The obtained FSH is especially useful for the prophylaxis and treatment of disorders and medical indications where FSH preparations are considered as useful remedies.

Method for purifying recombinant FSH

The present invention relates to nucleic acid molecules comprising a nucleic acid sequence coding for the &#x3b1;- and the &#x3b2;-chain of the human follicle stimulating hormone (FSH), respectively, which has been modified with respect to the codon usage in CHO cells. The present invention further relates to a recombinant nucleic acid molecule comprising such nucleic acid sequences and host cells containing such recombinant nucleic acid molecules, as well as their use in the production of recombinant human FSH. Finally, the present invention also relates to a method for producing host cells expressing human follicle stimulating hormone by transfecting cells in suspension culture under serum-free conditions with the recombinant nucleic acid molecule of the present invention.

FSH producing cell clone

A stable pharmaceutical formulation of erythropoietin is disclosed which contains tris-(hydrox-ymethyl)-aminomethane as stabilizer, whereby the formulation does not contain amino acids or human serumalbumin.

Erythropoietin solution formulation

Growing community of inventors

Schwetzingen, Germany

Stefan Arnold